HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Post Abbott Consent Decree; A Changed World for Immunoassay Vendors

Executive Summary

Abbott's prolonged problems with the FDA in the immunoassaay diagnostics market obviously created opportunities for competitors. Critics say, however, their response has been slow and none are able to step directly into Abbott's shoes. Companies initially viewed the situation as a short-term opportunity, but now they may become more aggressive as Abbott's grip on the market weakens.

You may also be interested in...



Biosite: Building a Solid Franchise

Biosite is one of a few diagnostic companies that has had to grapple with a literal run on its product--a point-of-care proprietary cardiovascular test that took off in the marketplace almost immediately after it was introduced in 2000. Now, it faces two challenges: the advent of competition from large in-vitro diagnostic companies and following up with a seond act as its explosive growth slows to more normal levels.

A Sobered Abbott Buys i-Stat

Abbott Laboratories' acquisition of i-Stat for $392 million reflects the promise and limitations of point-of-care diagnostics. A decade ago, i-Stat was a giddy startup, on a mission to revolutionize laboratory medicine with a handheld diagnostics system that could run basic blood tests rapidly at the patients' bedside. While it has accomplished much, it is far from creating a revolution. Meanwhile, the timing of the deal comes as Abbott emerges from a four-year nightmare with the FDA in which the FDA forced it to pull many of its important immunoassay tests off the market.

Roche Pays $1.4 Billion for Igen and Gets Peace of Mind

Roche's $1.4 billion acquisition of Igen left Igen shareholders gleeful and some Roche observers a bit wary of the high price tag. But by ending protracted litigation between the two companies, the deal protects one of Roche Diagnostics' core franchises, the central laboratory business.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV001791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel